TrialAntimicrobial agents and chemotherapy2025

A first-in-human phase I study to evaluate the safety, tolerability, and pharmacokinetics of a novel anti-influenza agent suraxavir marboxil in healthy Chinese subjects.

Qingqing Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.